Nov 13, 2025 08:05AM
Nov 13, 2025 08:05AM
Aug 20, 2025 08:01AM
Aug 20, 2025 08:00AM
Aug 13, 2025 08:01AM
Aug 13, 2025 08:01AM
Aug 5, 2025 08:00AM Tharimmune appoints Nancy Davis to board of directors
Aug 5, 2025 08:00AM
Aug 4, 2025 08:01AM
Aug 4, 2025 08:00AM
May 19, 2025 08:01AM
May 6, 2025 08:03AM
May 6, 2025 08:01AM
Apr 30, 2025 08:03AM Tharimmune (THAR) Appoints Clay Kahler and Gary Stetz to its Board
Apr 30, 2025 08:01AM
Apr 28, 2025 08:04AM
Apr 28, 2025 08:01AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM
Dec 16, 2024 08:04AM
Dec 16, 2024 08:00AM Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Oct 30, 2024 08:16AM
Oct 30, 2024 08:00AM
Jul 22, 2024 08:30AM
Jul 16, 2024 08:30AM
Jul 10, 2024 08:33AM
Jul 10, 2024 08:30AM
Jun 17, 2024 08:02AM Tharimmune (THAR) Reports Positive Type C Meeting with FDA for Phase 2 Program for TH104
Jun 17, 2024 08:00AM
Jun 11, 2024 07:54AM
Jun 10, 2024 08:28AM
Jun 10, 2024 08:00AM
Jun 10, 2024 08:00AM
Jun 10, 2024 08:00AM
Jun 10, 2024 08:00AM Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Jun 10, 2024 08:00AM
Apr 1, 2024 06:07AM
Feb 20, 2024 08:05AM
Feb 20, 2024 08:01AM
Feb 5, 2024 08:30AM
Nov 27, 2023 08:04AM
Nov 27, 2023 08:00AM Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
Nov 6, 2023 05:15PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All